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Abstract
 .  .A series of 2-substituted eicosapentaenoic acid EPA derivatives as ethyl esters have been synthesized and evaluated
as hypolipidemic and antithrombotic agents in feeding experiments in rats. Repeated administration of purified 2-methyl-
 .eicosapentaenoic acid and its deuterium analogues all as ethyl esters to rats resulted in a decrease in plasma triglycerides
and high density lipoprotein cholesterol. The 2-methyl-EPA analogues were, apparently, four times more potent than EPA
in inducing the triglyceride lowering effect. The 2-deuterium-2-methyl-EPA decreased plasma cholesterol level to ;40%.
A moderate enlargement of the liver was observed in 2-methyl-EPA treated rats. This was accompanied with an acute
reduction in the liver content of triglycerides and a stimulation of peroxisomal b-oxidation and fatty acyl-CoA oxidase
activity. The results suggest that the triglyceride-lowering effect of 2-methyl-EPA may be due to a reduced supply of fatty
acids for hepatic triglyceride biosynthesis because of increased fatty acid oxidation.
Platelet aggregation with ADP and A23187 was performed ex vivo in platelet-rich plasma, after administration of
different doses of the EPA-derivatives for five days. EPA and 2,2-dideuterium EPA had no effect on ADP-induced
aggregation, while 2-deuterium-, 2-methyl- and 2-deuterium-2-methyl EPA produced a biphasic effect, i.e. potentiation and
 .  .inhibition at low 250 mgrday kg body weight and higher doses 600–1300 mgrday kg body weight , respectively.
A23187-induced platelet aggregation was affected in a similar way by feeding the 2-substituted EPA derivatives, except that
2-deuterium-2-methyl EPA had no effect relative to EPA itself and that the inhibition was far greater than that for
 .ADP-induced aggregation ;100% inhibition with 600 mg 2-methyl-EPArday kg body weight . The ranking order of the
EPA-derivatives to affect platelet aggregation and to cause hypolipidemia was different, suggesting different mechanisms.
Our observations suggest that the effects of the EPA derivatives on platelet aggregation could be related to the degree of
bulkiness around C and that an asymmetric substitution at C caused inhibition of platelet aggregation while a symmetric2 2
Abbreviations: A23187, divalent cationophore; ADP, adenosine diphosphate; CMC, carboxymethyl cellulose; CoA, coenzyme A; D,
deuterium; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; GC, gas chromatograph; HDL, high density lipoprotein; MS, mass
spectroscopy; NMR, nuclear magnetic resonance; O.D., optical density; PC, phosphatidylcholine; PI, phosphatidylinositol; PLC,
phospholipase C; PPARa , peroxisome proliferator-activated receptor a; PRP, platelet rich plasma; VLDL, very low density lipoprotein
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substitution did not. It is suggested that the bulky, asymmetric derivatives inhibit platelet aggregation by altering platelet
membrane phospholipid packing. q 1998 Elsevier Science B.V.
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1. Introduction
Polyunsaturated fatty acids of fish origin, e.g.
 .eicosapenta--enoic acid EPA, 20 : 5 n-3 and docosa-
 .hexaenoic acid DHA 22 : 6 n-3 , are currently being
extensively investigated in laboratory and clinical
science. Included among a wide spectrum of biologi-
cal effects, these two fatty acids possess lipid lower-
ing and antithrombotic properties, and several studies
suggest an inverse relationship between the consump-
tion of marine foods, rich in n-3 fatty acids, and the
w xincidence of cardiovascular disease 1–4 . Fish oil
affects nearly every major pathway of hepatic fatty
acid metabolism. The hypotriglyceridemic effect of
dietary fish oil is attributed to increased fatty acid
 . w xoxidation mitochondrial andror peroxisomal 5–9 ,
w xinhibited lipogenesis 5,10,11 and accordingly, to
low formation and secretion of triglycerides and
w xVLDL in the liver 12–14 . Recently, we have ob-
served that highly purified EPA stimulates mitochon-
drial and peroxisomal b-oxidation and carnitine
palmitoyltransferase activity followed by diminished
w xlipogenesis 8 . It is noteworthy that relatively high
doses of highly purified EPA 1500 mgrday kg body
.weight are necessary for the reduction of plasma
triglycerides in rats. Also, in clinical studies, fairly
large amounts of n-3 fatty acids during an extended
period of time seem necessary to achieve significant
w xresults 9,15–17 . Our work with saturated 3-thia
fatty acids, lipid-lowering agents with both hy-
potriglyceridemic and hypocholesterolemic proper-
ties, have resulted in the same triglyceride lowering
w xeffect at a dose of 150 mgrday kg body weight 18 .
The hypolipidemic effect of 3-thia fatty acids is
probably exerted by blocking of mitochondrial b-
w xoxidation 19 .
Long-chain polyunsaturated fatty acids are rela-
tively poorly oxidized by the mitochondrial b-oxida-
tion system, and recently it has been shown that
introduction of a methyl group in the 2-position of
fatty acids is sufficient to prevent its b-oxidation in
w xmitochondria 20 . The results from experiments with
3-thia fatty acids initiated the search for simpler
derivatives of EPA that may result in hypolipidemia.
We have therefore synthesized 2-methyl-derivatives
 .of EPA with both hydrogen and deuterium Fig. 1 in
the 2-position, which might reveal a desireable lipid-
lowering effect with minimal side effects.
The present data support the concept that the
potency of long-chain fatty acids, saturated as poly-
unsaturated, as hypotriglyceridemic compounds de-
pend on their accessibility for b-oxidation. Further-
more, we also report results from studies on aggrega-
tion of platelets from rats treated with these hy-
potriglyceridemic agents. Numerous studies have
shown a dampening of platelet function, following
w xthe ingestion of fish and fish oils 21,22 . In the
present study, platelet aggregation was used to evalu-
ate the potency of the selected compounds as antiag-
gregating agents.
Fig. 1. Structural formula and names of synthesized fatty acid
analogs of eicosapentaenoic acid ethyl esters.
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2. Materials and methods
2.1. Chemicals
Palmitoyl-CoA was purchased from Sigma Chemi-
cals, whereas palmitic acid was purchased from
 .Aldrich-Chemie Steinheim, Germany . Eicosapen-
 .taenoic acid ethyl ester 95% pure was prepared at
Norsk Hydro AS, Research Centre, Porsgrunn, Nor-
way. All other chemicals were obtained from com-
mon commercial sources and were of reagent grade.
2.2. Synthesis of 2-methyl-eicosapentaenoic acid
deri˝ati˝es from eicosapentaenoic acid ethyl ester
A solution of BuLi in hexane 33.0 ml, 1.6 M,
.0.0495 mol was added with a syringe to diisopropyl
 .  .amine 5.0 g, 0.0495 mol in dried THF 40 ml at
y358C while stirring. This solution was further
cooled down to y708C, and EPA ethyl ester 14.8f,
.0.045 mol, 95% pure by GC was added dropwise at
this temperature for 1.5 h. The solution was kept at
 .y708C for a further 20 min before CH I 10 ml was3
added in one portion. The reaction mixture was held
at this temperature for 15 min and then slowly heated
to room temperature.
The reaction mixture was poured into a mixture of
 .  .water 100 ml and heptane 100 ml . The organic
 .phase was washed with water 2=75 ml , NaHCO3
 .  .75 ml , again with water 75 ml and dried over
Na SO for 24 h. 2-Methyl-EPA ethyl ester 14.7 g,2 4
.95% was collected after filtration and evaporated.
The purity was 90% by GC. This product was further
 .purified to 95% GC by prep-LC and evaporated.
The purity was 90% by GC. This product was further
 .purified to 95% GC by prep-LC.
 .  .  .  .MS mrz rel. intensity : 344 3 , 315 3 , 290 2 ,
 .  .  .  .  .  .275 7 , 201 20 , 175 17 , 119 46 , 91 78 , 79 100 .
1  .  3.  .  .H NMR 300MHz CDCl : 0.8 t,3H , 1.1 d,3H ,
 .  .  .  .1.2 t,3H , 1.4 m,1H , 1.55 s,1H , 1.75 m,1H ,
 .  .  .  .2.05 m,6H , 2.8 m,6H , 4.05 q, 2H , 5.2 m,10H .
2-Deuterium-eicosapentaenoic acid ethyl ester was
prepared in the same manner as 2-methyl-eicosa-
pentaenoic acid ethyl ester except heavy water 10 ml
.D O was added instead of CH I.2 3
2,2-Dideuterium-eicosapentaenoic acid ethyl ester
was prepared from 2-deuterium-eicosapentaenoic acid
ethyl ester that was quenched once more with 10 ml
D O.2
2-Deuterium-2-methyl-eicosapentaenoic acid ethyl
ester was prepared from 2-methyl-eicosapentaenoic
acid which was quenched with 10 ml D O.2
2.3. Animals and treatment
Male Wistar rats from Møllegaard Breading Labo-
ratory, Ejby, Denmark, weight 150–180 g, were
housed individually in metal wire cages in a room
maintained at 12 h light–dark cycles and at a constant
temperature of 20"38C. The animals were acclima-
tized for at least one week under these conditions,
before the start of the experiment.
 .The EPA derivatives and EPA all as ethyl esters
were suspended in 0.5% carboxymethyl cellulose
 .CMC with 0.5% tocopherol and administered by
gastric intubation at doses of 250, 600 and
1300 mgrday kg body weight in a volume of 0.7–
1.0 ml once a day for five days. The control animal
groups received only CMC and 0.5% tocopherol. All
animals had free access to water and food. The food
w xcomposition was as earlier described 23 , containing
 .55% carbohydrate wrw , 25% protein and 2.1% fat
 .wrw and all necessary minerals and vitamins.
The body weights of the rats were measured daily.
At the end of the experiments, the rats were fasted
overnight and weighed. Under light halothane anaes-
thesia, cardiac puncture was performed to obtain
 .blood samples in EDTA . The livers were removed
and immediately chilled on ice and weighed. Plasma
was prepared from the blood samples by centrifuga-
tion at 1000=g for 10 min.
2.4. Preparation of subcellular fractions
Livers from individual rats were homogenized in
an ice-cold sucrose medium 0.25 M sucrose in 10 mM
.HEPES buffer, pH 7.4, and 1 mM EDTA . The result-
ing nuclearqpostnuclear fraction was taken as the
total homogenate, and a light mitochondrial enriched
w xfraction was isolated as previously described 24 . All
procedures were performed at 0–48C. The different
fractions were stored at y808, until analyzed.
2.5. Analytical methods
Protein was assayed by Bio-Rad protein assay kit
 .Bio-Rad, Richmond, CA . Lipid analyses were car-
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ried out by the Monotest cholesterol enzymatic kit
 .Boehringer Mannheim, Germany , the Monotest
phospholipid enzymatic kit Boehringer, Mannheim,
.Germany and the Biopak Triglyceride enzymatic kit
 .Biotrol, Paris, France .
w xEnzymatic activities of fatty acyl-CoA oxidase 25
and peroxisomal b-oxidation palmitoyl-CoA depen-
. w xdent dehydrogenase 26 were determined as de-
scribed earlier.
2.6. Platelet aggregation studies
Blood was collected by cardiac puncture into 1r10
volume of 0.22 M Na -citrate and centrifuged at G3 max
s180=g at room temperature for 15 min. The
platelet-rich plasma so obtained was used for deter-
mination of platelet aggregation with A23187 2.5
.  .and 5mM and ADP 1 and 4 mM in a Payton Dual
 .Channel Aggregometer 200 ml samples at room
temperature and a stirring speed of 900 rpm.
2.7. Presentation of results
Variation in response from animal to animal was
estimated separately for selected enzymes and lipids
in the group of control and experimental animals.
Data are presented as mean"SD. Six animals in
each experimental group and six controls were used.
Data were statistically analyzed by Student’s t-test.
3. Results
3.1. Body and li˝er weight
The rats fed normolipidemic diet supplemented
with EPA, 2-methyl-EPA and their deuterium ana-
logues gained weight per day at the same rate as
controls. Food consumption was similar in each ex-
perimental group, irrespective of the dietary regime,
indicating that the appetite was not affected and that
the n-3 fatty acid analogues were well tolerated. All
animals treated with fatty acids at various doses
appeared healthy, had normal body weight and nor-
 .mal hepatic concentration of protein data not shown
and looked and behaved normal. No hepatomegaly
resulted after feeding EPA, 2-deuterium-EPA and
2,2-dideuterium-EPA even at a dose of
1300 mgrday kg body weight, whereas a moderate
enlargement of the liver was observed in 2-methyl
 .EPA treated rats Table 1 .
Table 1
Dose-dependent changes of liver weight and liver lipids in rats treated with EPA and structural analogs of 2-methyl-EPA all as ethyl
. aesters for 5 days
 .Parameters Compound Dose mgrday kg body weight
0 250 600 1300
 .Relative liver weight grbody weight=100% EPA 3.46"0.04 3.54"0.04 3.51"0.17 3.74"0.13
2-D-EPA 3.12"0.03 3.24"0.12 3.14"0.08 3.05"0.06
2,2-diD-EPA 3.08"0.04 2.97"0.02
b2-methyl-EPA 3.29"0.13 3.44"0.14 3.60"0.16 3.79"0.08
2-D-2-methyl-EPA 3.23"0.16 3.26"0.13 3.42"0.31 3.60"0.18
 .Hepatic triglycerides mmolrg liver EPA 5.45"1.01 5.10"1.18 4.71"0.89 4.80"0.74
2-D-EPA 4.37"1.08 5.48"0.48 6.59"2.81 6.31"0.84
2,2-diD-EPA 4.51"0.04 4.52"0.10
b b2-methyl-EPA 6.31"0.75 4.58"0.92 4.18"0.28 4.95"0.14
b b b2-D-2-methyl-EPA 5.83"0.33 3.77"0.62 4.15"0.26 4.84"0.35
 .Hepatic cholesterol mmolrg liver EPA 11.05"0.59 12.40"1.26 12.17"0.21 12.42"0.41
2-D-EPA 12.22"0.58 13.12"0.29 13.50"0.29 13.13"0.09
2,2-diD-EPA 10.52"0.26 10.90"0.21
2-methyl-EPA 12.99"0.54 12.93q0.72 13.53"0.06 13.25"0.25
2-D-2-methyl-EPA 12.56"0.43 12.62"0.38 12.50"0.60 12.15"0.84
a Values are expressed as means"SD for six animals in each experimantal group.
b P-0.05 as compared to controls.
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Table 2
 . aDose-dependent changes of serum lipids in rats treated with EPA and structural analogues of methyl-EPA all as ethyl esters for 5 days
 .Parameters Compound Dose mgrday kg body weight
0 250 600 1300
b .Serum Triglycerides mmolrl EPA 0.99"0.18 1.04"0.28 0.86"0.13 0.69"0.10
2-D-EPA 1.05"0.06 1.27"0.25 0.82"0.17 0.95"0.16
b2,2-diD-EPA 0.56"0.12 0.35"0.06
b b2-methyl-EPA 1.08"0.13 0.99"0.11 0.52"0.03 0.70"0.08
b b b2-D-2-methyl-EPA 0.93"0.06 0.70"0.08 0.64"0.20 0.58"0.14
 .Serum Cholesterol mmolrl EPA 1.88"0.06 1.74"0.27 1.51"0.35 1.69"0.15
2-D-EPA 1.71"0.18 1.52"0.20 1.48"0.16 1.59"0.24
2,2-diD-EPA 1.91"0.19 1.64"0.11
2-methyl-EPA 1.62"0.02 1.50"0.14 1.41"0.31 1.49"0.29
b2-D-2-methyl-EPA 1.92"0.08 1.77"0.23 1.49"0.26 1.13"0.04
b .Serum HDL-cholesterol mmolrl EPA 1.33"0.02 1.36"0.18 1.10"0.22 1.02"0.12
2-D-EPA 1.17"0.09 1.07"0.08 0.98"0.13 1.13"0.19
b2,2-diD-EPA 1.47"0.01 1.16"0.05
b2-methyl-EPA 1.35"0.02 1.19"0.13 1.22"0.22 1.08"0.20
b2-D-2-methyl-EPA 1.59"0.18 1.41"0.21 1.29"0.06 0.92"0.06
aValues are presented as means"SD from 6 animals.
b P-0.05 compared to controls.
3.2. Serum and hepatic lipids
w xIn keeping with previous observations 8,9 , serum
triglycerides and serum HDL-cholesterol were signif-
icantly lowered after administration of EPA at a dose
 .of 1300 mgrday kg body weight Table 2 . Repeated
administration of this n-3-fatty acid only marginally
 .affected the serum cholesterol Table 2 , hepatic
 .triglycerides and hepatic cholesterol Table 1 . It has
recently been observed, however, that hypocholes-
terolemic effect is observed in EPA-treated rats for a
w xlonger feeding time 9 . When 2-methyl-EPA was
Table 3
Dose-dependent changes of peroxisomal b-oxidation and fatty acyl-CoA oxidase activity in rats treated with EPA and structural
 . aanalogues of 2-methyl-EPA all as ethyl esters for 5 days
 .Parameters Compound Dose mgrday kg body weight
0 250 600 1500
b .Peroxisomal b-oxidation nmolrmin mg protein EPA 3.35"0.11 3.50"0.21 3.33"0.22 4.36"0.23
b2-D-EPA 3.07"0.50 3.50"0.52 4.28"0.34 3.61"0.31
b2,2-diD-EPA 3.02"0.33 4.35"0.41
b b b2-methyl-EPA 3.50"0.47 4.58"0.22 6.60"0.29 7.55"1.68
b b b2-D-2-methyl-EPA 2.85"0.15 4.16"0.70 4.30"0.41 7.03"1.42
b .Fatty acyl-CoA oxidase nmolrmin mg protein EPA 6.18"0.12 6.36"0.55 6.29"0.12 7.99"0.55
b2-D-EPA 6.15"0.72 6.95"0.22 7.94"0.44 7.18"0.28
b2,2-diD-EPA 5.92"0.36 7.68"0.28
b b b2-methyl-EPA 7.26"0.54 9.22"0.72 11.53"0.93 11.94"1.26
b b b2-D-2-methyl-EPA 6.52"0.74 8.79"1.20 9.12"0.55 12.43"2.07
a The enzyme activities were measured in the light mitochondrial fraction. Values are presented as mean"SD from 6 animals.
b P-0.05 as compared to controls.
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given, the serum triglycerides decreased, and at a
dose of 600 mgrday kg body weight a 50% reduction
 .of serum triglycerides resulted Table 2 . This meth-
ylated n-3 fatty acid caused no reduction of serum
 .nor hepatic cholesterol Table 1 . However, it low-
 .ered serum HDL-cholesterol Table 2 and hepatic
 .triglycerides Table 1 . 2-Deuterium-2-methyl EPA
reduced both plasma and hepatic triglycerides, in
addition to reduced plasma cholesterol and plasma
HDL-cholesterol. 2,2-dideuterium EPA reduced
plasma triglycerides, cholesterol and HDL-
cholesterol.
3.3. Peroxisomal b-oxidation
The activities of peroxisomal b-oxidation and fatty
acyl-CoA oxidase were significantly increased 1.3-
.fold after administration of EPA at a dose of
 .1300 mgrday kg body weight Table 3 . Administra-
tion of deuterium analogues of EPA stimulated the
peroxisomal enzyme activities to a similar magnitude,
or even higher, at a dose of 600 mgrday kg body
 .weight Table 3 . Repeated administration of 2-
methyl-EPA caused a dose-related increase of the
peroxisomal enzyme activities. At the highest dose
 .1300 mgrday kg body weight , a 2.3-fold increase of
peroxisomal b-oxidation and 1.8-fold of fatty acyl-
 .CoA oxidase was revealed Table 3 .
3.4. Platelet aggregation
Aggregation of platelets from rats in the different
groups was induced with the divalent cationophore
 .A23187 and adenosine diphosphate ADP . In
platelets from control rats, 1 mM ADP gave a rapid
 .shape change increase in O.D. followed by a mod-
 .est aggregation response decrease in O.D. which
was reversible with a maximum at 1 min; at 4 mM
ADP a greater, reversible aggregation with maximum
  . .at 2 min was observed Fig. 2 A , upper two tracings .
In the same control, platelets A23187, at both 2.5 and
5 mM, gave a rapid, transient shape-change response
followed by maximal, irreversible aggregation Fig.
 . .2 A , lower two tracings . Feeding of rats with EPA
and its two derivatives had a small, inhibitory effect
on platelet aggregation in response to 4 mM ADP,
while it caused a marked reduction of the aggregation
  ..in response to 1 mM ADP Fig. 2 B–D . Similarly,
  ..dietary administration of EPA Fig. 2 B and 2-de-
Fig. 2. Platelet aggregation in platelet-rich plasma from rats fed
on EPA and its derivatives for 5 days 1300mgrdaykg body
.  . weight . Upper two tracings, ADP: 1mM trace 1 , 4 mM trace
.  . 2 . Lower two tracings, A23187: 2.5mM trace 3 , 5mM trace
.4 . A scontrol; BsEPA; Cs2-deuterium EPA; and Ds2-
methyl EPA. The tracings are representative for three rats in each
group.
  ..uterium EPA Fig. 2 C produced a reduction in
aggregation induced by the two concentrations of
A23187. In sharp contrast, however, administration
of dietary 2-methyl EPA actually abolished the ag-
gregatory response to A23187 at both 2.5 and 5mM,
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leaving only a sluggish shape-change response to
  ..occur Fig. 2 D . Thus, feeding rats with EPA and
its derivatives for 5 days diminished platelet aggrega-
tion to the low dose of ADP and to both doses of
A23187, except that feeding with 2-methyl EPA con-
verted the pronounced and irreversible A23187-in-
duced platelet aggregation response seen in control
rats to a faint, reversible shape change response.
Aggregation responses to the two agonists were
determined in platelets from rats fed on increasing
concentrations of EPA and its derivatives for 5 days
 .Figs. 3–6 . In these dose-response experiments feed-
ing of 1300 mgrkg day of EPA and 2,2-dideuterium
EPA for 5 days had no effect on aggregation by
 .1 mM ADP Fig. 3 . In accordance with the results
 .obtained with 1300 mgrkg day of EPA Fig. 2 , there
was also no effect on aggregation produced by 4 mM
ADP by administration of 1300 mgrkg day of EPA,
and the same result was obtained with 2,2-dide-
 .uterium EPA Fig. 4 . However, feeding with 2-
Fig. 3. Dose-dependent changes of the initial rate of platelet
aggregation induced by 1mM ADP in platelet-rich plasma from
 .  .rats fed EPA – v – , 2-deuterium-EPA – ‘ – , 2-methyl-EPA
 .  .
– I – , 2-deuterium-2-methyl-EPA y ^ y and 2,2-dide-
 .uterium-EPA – B – . Data represent mean"SD derived from
three separate experiments.
Fig. 4. Dose-dependent changes of the initial rate of platelet
aggregation induced by 4 mM ADP in platelet-rich plasma from
 .  .rats fed EPA – v – , 2-deuterium-EPA – ‘ – , 2-methyl-EPA
 .  .
– I – , 2-deuterium-2-methyl-EPA y ^ y and 2,2-dide-
 .uterium-EPA – B – . Data presents mean"SD from three sepa-
rate experiments.
Fig. 5. Dose-dependent changes of the initial rate of platelet
aggregation induced by 2,5mM A 23187 in platelet-rich plasma
 .  .from rats fed EPA – v – , 2-deuterium-EPA – ‘ – , 2-methyl-
 .  .EPA – I – , 2-deuterium-2-methyl-EPA y ^ y and 2,2-di-
 .deuterium-EPA – B – . Data are presented as mean"SD from
three separate experiments.
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methyl EPA, 2-deuterium EPA and 2-deuterium-2-
methyl EPA produced biphasic dose-response curves
with an increase in the aggregation response to both
doses of ADP at 250 mgrkg day and a progressive
inhibition of aggregation as the dose was increased
 .further Figs. 3 and 4 . The biphasic pattern was most
 .expressed for aggregation with 1 mM ADP Fig. 3 .
The aggregation response to 2.5 mM A23187 de-
creased progressively and in parallel with increasing
dose of EPA, 2,2-dideuterium EPA and 2-deuterium-
2-methyl EPA to ;30% inhibition at 1300 mgrkg
day, while 2-deuterium EPA gave a slightly greater,
progressive inhibitory effect with 70% inhibition at
 .1300 mgrkg day Fig. 5 . In sharp contrast, and simi-
 .lar to the observation in Fig. 2 D , 2-methyl EPA
inhibited the aggregation response to 2.5 mM A23187
by 90% at 250 mgrkg day and abolished aggregation
 .at higher doses Fig. 5 . The aggregation response to
5 mM A23187 was not affected by EPA and 2,2-dide-
uterium EPA in the concentration range tested, but
Fig. 6. Dose-dependent changes of the initial rate of platelet
aggregation induced by 5mM A 23187 in platelet-rich plasma
 .  .from rats fed EPA – v – , 2-deuterium-EPA – ‘ – , 2-methyl-
 .  .EPA – I – , 2-deuterium-2-methyl-EPA y ’ y and 2,2-di-
 .deuterium-EPA – B – . Data are presented as mean"SD from
three separate experiments.
gave a biphasic dose-response pattern that was remi-
niscent of ADP for 2-deuterium EPA and 2-de-
 .uterium-2-methyl EPA Fig. 6 . Administration of
2-methyl EPA caused profound inhibition of aggrega-
tion with 5mM A23187 although without abolition at
 .the higher doses Fig. 6 . Thus, administration of
EPA and 2,2-dideuterium EPA to the rats were with-
out effect, while the 2-methyl-, 2-deuterium- and
2-deuterium-2-methyl derivatives of EPA had equipo-
tent stimulatoryrinhibitory effect on ADP-induced
platelet aggregation. For the A23187-induced platelet
aggregation, 2-methyl EPA had an outstanding,
only-inhibitory effect while EPA and the other
derivatives affected aggregation to different degrees.
4. Discussion
3-Thia fatty acids and n-3-fatty acids are hypolipi-
demic substances, i.e. they reduce serum concentra-
w xtions of cholesterol and triglycerides 15,27 , induce
proliferation of peroxisomes in rats and have several
effects on intermediary lipid metabolism in common.
Thus, these hypolipidemic compounds may excert
their functions as lipid-lowering agents and peroxi-
some proliferators, in a similar fashion.
The 3-thia-fatty acid, however, is a fatty acid
analogue in which the 3-methylene group of a normal
saturated fatty acid is substituted with a sulfur atom.
The analogue has many of the biochemical and bio-
w xphysical properties of a fatty acid 23 , but it cannot
w xbe b-oxidized in the mitochondria 19 . Thus, it is a
paradox that these fatty acid derivatives cannot be
themselves oxidized, but can induce hepatic fatty acid
b-oxidation and lower plasma triglycerides after ad-
w xministration 15,27 .
The correlation coefficient between the specific
activities of fatty acyl-CoA oxidase andror peroxiso-
mal b-oxidation and the volume fraction of peroxi-
somes, based on our experiments with sulfur-sub-
stituted fatty acid analogues, was very good to excel-
w xlent 19 . Therefore, we suppose that fatty acyl-CoA
oxidase activity and peroxisomal b-oxidation are good
indicators of peroxisome proliferation.
The present study confirms earlier observations
w x8,9 , that treatment with pure EPA stimulates peroxi-
somal b-oxidation and fatty acyl-CoA oxidase activ-
 .ity Table 3 . Furthermore, we have found here that
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there are clear structural requirements for peroxiso-
mal b-oxidation in rat liver. From the investigation of
 .the structural analogues of EPA Fig. 1 , it can be
concluded that the most effective stimulator has a
methyl group as the substituent on the carbon 2 of the
main chain. This observation is in agreement with
w xdata obtained by Lundgren et al. 28 , where 2-ethyl-
hexaenoic acid was a more effective peroxisome
proliferator than hexanoic acid. Methyl-substituted,
non-b-oxidizable long-chain dioic acids have been
w xfound to have peroxisome proliferating potential 28 .
Based on the results obtained with 3-thiadicarbo-
 .xylic acid blocked for v- and b-oxidation , tetrade-
 .cylthioacetic acid blocked for b-oxidation and te-
tradecylthiopropionic acid a v- and b-oxidizable
.fatty acid , it is quite evident that availability to
b-oxidation is a determinant for peroxisome prolifer-
w xating effect 18 . Substitution of H with deuterium
and CH at carbon 2 of EPA stimulate the peroxiso-3
mal b-oxidation and fatty acyl-CoA oxidase activity
 .compared to EPA and 2-methyl-EPA Table 3 . Thus,
data obtained with deuterium analogues seem to em-
phasize the importance of the metabolic availability.
The order of potency with respect to stimulation of
peroxisomal activities was 2-methyl-EPAs2-deute-
rium-2-methyl-EPA ) EPA s 2,2-dideuterium-EPA
 .)2-deuterium-EPA Table 3 . Whether the potency
of selected compounds as proliferators of peroxi-
somes depends on their accessibility for b-oxidation,
should be considered. As for the sulfur-substituted
fatty acids, the experimental data suggest that the
minimal structural requirement for peroxisomal pro-
liferation may be a carboxylic acid group linked to a
hydrophobic backbone with poor susceptibility to
b-oxidation. The stimulation of peroxisomal activities
with EPA and their analogs, but not with palmitic
w xacid 8 , conforms to the previously defined require-
w xment for initiation of peroxisomal proliferation 23 .
w xForman et al. 29 have found hypolipidemic drugs,
including tetradecylthioacetic acid, and polyunsatu-
rated fatty acids to be ligands for the peroxisome
 .proliferator-activated receptor a PPARa , and also
they conclude that a carboxyl group on the fatty acid
is required for activation of PPARa . As a single fatty
acid which is poorly oxidized by mitochondria, EPA
has been established as a sufficient stimulus for
w xinduction of peroxisomal b-oxidation 9 . The hy-
drophobicity of the compounds may relate to their
accessibility for activation or to their rate of metabolic
clearance. As 2-methyl-EPA was a more effective
inducer of fatty acyl-CoA oxidase than EPA, poor
susceptibility to b-oxidation is, apparently, a determi-
nant of peroxisome proliferating potency.
The present study confirms earlier observations
w x8,9 that treatment with EPA decreases levels of
 .serum triglycerides Table 2 . In the dose-dependent
studies, 2-methyl-EPA was able to reduce serum
triglycerides and HDL-cholesterol even more as com-
pared to EPA. Also, substitution of deuterium in the
2-position of the carbon chain tended to reduce the
serum lipids. Thus, the order of potency with respect
to the lipid lowering effects and peroxisomal b-
oxidation, was 2-methyl-EPA s 2-deuterium-2-
methyl EPA ) 2,2-dideuterium EPA s EPA ) 2-
deuterium-EPA. 2-Methyl-EPA reduced the liver con-
 .tent of triglycerides Table 1 . Thus, one hypothesis
for the triglyceride-lowering effect observed with
these polyunsaturated fatty acid analogues is that the
effect is due to increased fatty acid oxidation accom-
panied by a reduction in the availability of fatty acids
for triglyceride biosynthesis. EPA can increase b-
w xoxidation in cultured hepatocytes 8 and there is
evidence that this pathway is the primary site for the
w xhypolipidemic effect of n-3 fatty acids in rats 30–32
w xas well as in humans 33 . The increase in fatty acid
oxidation is able to divert fatty acids from triglyc-
 .eride synthesis Table 3 and from the serum com-
w xpartment 31 . The second hypothesis asserts that the
diversion of fatty acids to b-oxidation would also
increase the rate of transfer of fatty acids from the
plasma into liver, giving a further reduction in plasma
fatty acid levels.
Feeding rats 2-methyl- and 2-deuterium-substituted
EPA derivatives had profound inhibitory effects on
ex vivo platelet aggregation induced by ADP and
A23187, particularly at low concentrations of the
agonists. Unmodified EPA and 2,2-dideuterium-EPA,
however, had no effect in our experiments, except for
a 30% inhibition with 1300 mgrkg day at the lowest
A23187 concentration. EPA is known to replace
arachidonic acid in the platelet phospholipids of rats
w x w xfed on fish oil 34,35 , EPA 36 or EPA precursors
w x37 without affecting platelet function, which is in
accordance with the present results. The cyclooxy-
genase and lipooxygenase products of EPA liberated
from the phospholipids may also counteract platelet
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w xstimulation 38,39 . Thus, replacement of arachidonic
acid by EPA in the phospholipids may lower the
amount of eicosanoids that promote platelet activa-
tion. It is noteworthy that EPA is incorporated in PC
and PI and these molecular species may be unsuitable
substrates for PLC and PLA which are activated2
w xduring platelet stimulation 40 . The inhibition of rat
platelet aggregation by dietary 2-substituted EPA
shown in the present study is, therefore, hardly due to
a putative metabolism of these derivatives through
the cyclooxygenase pathway. The dose-response ex-
periments revealed a ranking potency order for inhi-
bition, at the highest doses used, of 2-deuterium-
EPAs 2-methyl-EPAs2-deuterium-2-methyl-EPA
)EPAs2,2-dideuterium-EPA for ADP, and 2-
methyl-EPA)2-deuterium-EPA)EPAs2,2-dideu-
terium-EPA s 2-deuterium-2-methyl-EPA for
 .A23187 Figs. 3–6 . The most conspicuous similarity
among these ranking orders and that for stimulation
 .of peroxisomal activities above is that 2-methyl-EPA
produces the greatest effect. One reason for this
might be that 2-methyl EPA is incorporated into the
 .phospholipids data to be published . The most out-
standing dissimilarity, however, is for 2-deuterium-
EPA which, at the highest dose used, did not stimu-
late peroxisomal activities, but produced maximal
inhibition of ADP-induced aggregation and about
half-maximal inhibition of A23187-induced aggrega-
tion. The different ranking order of the EPA-deriva-
tives to affect platelet aggregation and to cause hy-
polipidemia suggests different mechanisms.
Inhibition of platelet aggregation by both agonists
used by the EPA derivatives was most expressed at
the lower agonist concentration. Thus, the inhibition
could be overcome by increase of the agonist concen-
tration. For A23187-induced aggregation, the 2-
mono-substituted EPA derivatives were more in-
hibitory than 2-di-substituted EPA at 1300 mgrkg
day, and the same pattern is apparent for inhibition of
ADP-induced aggregation at 600 mgrkg day. Fur-
thermore, the heavier CH -substitution produces more3
 .inhibition than the lighter deuterium D -substitution.
It is expected that substitution of 1H with CH at the3
C carbon in EPA would increase the bulkiness2
around C . Feeding the rats with the highest doses of2
2-methyl EPA produced the most pronounced inhibi-
tion of both ADP- and A23187-induced platelet ag-
gregation. Assuming that substitution with both D
and CH at C would also increase bulkiness, and3 2
feeding the rats this derivative caused maximal inhi-
bition of ADP-induced aggregation, but had no effect
relative to EPA on A23187-induced aggregation.
Consequently, our results may indicate that an in-
crease in the bulkiness around C tends to inhibit2
platelet aggregation. If these 2-methyl-derivatives of
EPA were incorporated into the platelet phospho-
lipids, the inhibition of platelet aggregation may have
been due to an alteration of acyl-packing of the
membrane phospholipids. Indeed, 2-methyl EPA is
found in phospholipids in in-vitro experiments data
.to be published .
1 2  .However, substitution of one H with H D at C2
 .asymmetric substitution in EPA would cause a neg-
ligible change in bulkiness. Nevertheless, we ob-
served strong inhibition of both ADP- and A23187-
induced platelet aggregation after feeding the rats
with the highest dose of the asymmetric, 2-D substi-
tuted EPA. On the other hand, when the rats were fed
with EPA, which had both 1H-substituted by D at the
 .C carbon symmetric substitution , no inhibition of2
platelet aggregation with both agonists relative to
non-derivatized EPA was observed. Substitution of
one
1H with CH at C is also a monosubstitution3 2
which produced strong inhibition. Our results, there-
fore, show that feeding with asymmetrically substi-
tuted EPA produces inhibition of platelet aggregation
ex vivo, while feeding the rats symmetrical substi-
tuted EPA does not. The only exception from this
apparent rule was our results from feeding rats with
the asymmetric 2-deuterium-2-methyl EPA in the
experiments with A23187-induced aggregation.
The effect of the dietary 2-substituted EPA was
biphasic, i.e. they stimulated and inhibited platelet
aggregation at low and high doses, respectively. This
phenomenon is known from studies on the effect of
amphiphilic cationic drugs phenothiazines, tricyclic
.antidepressants on activation of human platelets with
w xthrombin 41 .
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